SFRP5 and coronary artery disorder: Conversely, Sfrp5 antagonizes Wnt signaling, particularly the non-canonical pathway, by binding to Wnt ligands, thereby reducing inflammation and oxidative stress in adipose and vascular tissues 59,60, which may protect against metabolic syndrome and CAD 61,62.